Entrada Therapeutics
TRDA
47 hedge funds and large institutions have $334M invested in Entrada Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
167% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 6
56% more capital inflows, than outflows
Capital inflows: $10.3M | Capital outflows: $6.63M
42% more funds holding
Funds holding: 33 → 47 (+14)
0.53% more ownership
Funds ownership: 78.15% → 78.69% (+0.53%)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$878K |
| 3 |
Citigroup
New York
|
+$867K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$742K |
| 5 |
BlackRock
New York
|
+$708K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.76M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$1.5M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$1.19M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1M |
| 5 |
Goldman Sachs
New York
|
-$841K |
TRDA Hedge Fund Activity: Q4 2022 in Review
47 of the 6,241 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q4 2022, worth a combined $334M — down 14% from $386M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new TRDA positions and 3 closed out — a net gain of 14 holders — while 16 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.96M. The largest seller was Redmile Group, cutting an estimated $1.76M.
- 47 institutional investors held Entrada Therapeutics (TRDA) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $334M of Entrada Therapeutics stock for Q4 2022, down 14% quarter-over-quarter.
- 17 funds opened new Entrada Therapeutics positions in Q4 2022 and 3 closed out, a net change of +14 holders.
- The largest Entrada Therapeutics buyer in Q4 2022 was Susquehanna International Group, an estimated $1.96M added.
- The largest Entrada Therapeutics seller in Q4 2022 was Redmile Group, an estimated $1.76M sold.
Based on aggregated 13F filings for Q4 2022.